PMID: 9420037Jan 7, 1998Paper

Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide

Antimicrobial Agents and Chemotherapy
C A PeloquinR W Jelliffe

Abstract

Isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) are the most important drugs for the treatment of tuberculosis (TB). The pharmacokinetics of all three drugs in the plasma of 24 healthy males were studied as part of a randomized cross-over phase I study of two dosage forms. Subjects ingested single doses of INH at 250 mg, RIF at 600 mg, and PZA at 1,500 mg. Plasma was collected for 36 h and was assayed by high-performance liquid chromatography. The data were analyzed by noncompartmental, iterative two-stage maximum a posteriori probability Bayesian (IT2B) and nonparametric expectation maximization (NPEM) population modeling methods. Fast and slow acetylators of INH had median peak concentrations in plasma (C[max]) of 2.44 and 3.64 microg/ml, respectively, both of which occurred at 1.0 h postdose (time of maximum concentrations of drugs in plasma [T(max)]), with median elimination half-lives (t1/2) of 1.2 and 3.3 h, respectively (by the NPEM method). RIF produced a median C(max) of 11.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 3.4 h. PZA produced a median C(max) of 28.80 microg/ml, a T(max) of 1.0 h, and a t1/2 of 10.0 h. The pharmacokinetic behaviors of INH, RIF, and PZA were well described by the three methods used....Continue Reading

References

Jul 1, 1979·The Journal of Antimicrobial Chemotherapy·R P MoutonJ de Wael
Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Dec 17, 1992·The New England Journal of Medicine·S E BerningC A Peloquin
Feb 2, 1995·The New England Journal of Medicine·K B PatelH M Crowe
Jan 1, 1994·The Annals of Pharmacotherapy·C A Peloquin, S E Berning
Oct 7, 1993·The New England Journal of Medicine·C A PeloquinS E Berning
Sep 1, 1996·The Annals of Pharmacotherapy·C A PeloquinG T Gerena
Aug 15, 1997·Annals of Internal Medicine·J SahaiD W Cameron

❮ Previous
Next ❯

Citations

Sep 22, 2020·Therapeutic Drug Monitoring·Julian D OtalvaroAndres F Zuluaga
Nov 4, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David C PerlmanUNKNOWN AIDS Clinical Trials Group 309 Team
May 12, 2011·Journal of Clinical Pharmacology·Rui ZhuCourtney V Fletcher
Aug 29, 2007·Antimicrobial Agents and Chemotherapy·Tawanda GumboGeorge L Drusano
Oct 13, 2010·Antimicrobial Agents and Chemotherapy·Zahoor AhmadEric L Nuermberger
May 6, 1999·American Journal of Respiratory and Critical Care Medicine·R S MaloneC A Peloquin
Jan 22, 2021·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·N Ben FredjK Aouam
Apr 23, 2013·Clinical Pharmacokinetics·Antonello Di PaoloMario Del Tacca
Jul 18, 2002·Antimicrobial Agents and Chemotherapy·John E ConteElisabeth Zurlinden
Jul 18, 2002·Antimicrobial Agents and Chemotherapy·Eric DannaouiUNKNOWN Eurofung Network
Jan 15, 2014·BMC Infectious Diseases·Vanina MeyssonnierJérôme Robert
Aug 26, 1998·Therapeutic Drug Monitoring·C A Peloquin
Nov 22, 2012·Journal of Clinical Pharmacy and Therapeutics·R C Milán SegoviaS Romano Moreno
Oct 14, 2006·Therapeutic Drug Monitoring·Joyce PullenLuc J I Zimmermann
May 29, 1999·Antimicrobial Agents and Chemotherapy·J E ConteE Zurlinden
Apr 27, 2019·Current Protocols in Pharmacology·Nivea M F VoelknerHartmut Derendorf
May 22, 2009·The Journal of Antimicrobial Chemotherapy·Manju Y KrishnanMichael T Collins
Nov 7, 2006·Journal of Veterinary Pharmacology and Therapeutics·C A PeloquinM Zhu
Oct 28, 2019·American Journal of Respiratory and Critical Care Medicine·Taylor W ForemanDeepak Kaushal
Apr 17, 2004·Clinical Pharmacokinetics·John E ConteElisabeth Zurlinden
May 3, 2019·Clinical Pharmacokinetics·Ahmed Aliyu AbulfathiHelmuth Reuter
Aug 21, 2008·The Journal of Antimicrobial Chemotherapy·Marta SousaMarta Boffito
Feb 6, 2015·Journal of Korean Medical Science·Ina JeongJae-Ho Lee
Mar 13, 2015·Antimicrobial Agents and Chemotherapy·Ana Requena-MéndezDavid A J Moore
Feb 23, 2021·Clinical Pharmacokinetics·Stijn W van BeekUNKNOWN Isoniazid Precision Dosing Group
Nov 15, 2019·Therapeutic Drug Monitoring·Carlos A RodriguezYuli Agudelo
Sep 13, 2008·American Journal of Respiratory and Critical Care Medicine·Reynaldo DietzeJohn L Johnson
Nov 9, 2018·Clinical Pharmacokinetics·Alper DaskapanJan-Willem C Alffenaar
May 20, 2015·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S NguyenE Senneville
Nov 1, 2008·Personalized Medicine·Pedro Eduardo FerreiraJosé Pedro Gil
May 1, 2007·Personalized Medicine·Cedric J WerelyPaul D van Helden
Jun 10, 2015·Antimicrobial Agents and Chemotherapy·Marieke G G SturkenboomJan-Willem C Alffenaar
Jun 14, 2017·Antimicrobial Agents and Chemotherapy·Maxwell T ChirehwaPaolo Denti
Mar 22, 2006·Journal of Pharmacokinetics and Pharmacodynamics·Ivelina GueorguievaMalcolm Rowland

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.